brukinsa
medison pharma ltd - zanubrutinib - capsules - zanubrutinib 80 mg - • brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• brukinsa is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm).• brukinsa is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (mzl) who have received at least one anti-cd20-based regimen.• brukinsa is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll).
luvinsta capsules hard 20mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - fluvastatin - hard capsule - fluvastatin 20 mg - lipid modifying agents
luvinsta capsules hard 40mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - fluvastatin - hard capsule - fluvastatin 40 mg - lipid modifying agents
brukinsa capsule
beigene switzerland gmbh - zanubrutinib - capsule - 80mg - zanubrutinib 80mg - antineoplastic agents
kyleena insert (extended-release)
bayer inc - levonorgestrel - insert (extended-release) - 19.5mg - levonorgestrel 19.5mg - contraceptives
mirena insert (extended-release)
bayer inc - levonorgestrel - insert (extended-release) - 52mg - levonorgestrel 52mg - contraceptives
brukinsa™ capsule 80mg
beigene singapore pte. ltd. - zanubrutinib - capsule - zanubrutinib 80mg
kappanogest 0,03 mg/2 mg filmtabletten